Can I read Safety of Divalproex Sodium in Migraine Prophylaxis: An Open-Label, Long-term Study on EtoBox?

Safety of Divalproex Sodium in Migraine Prophylaxis: An Open-Label, Long-term Study by Stephen D. Silberstein; Stephen D. Collins; Long-term Safety of Depakote in Headache Prophylaxis Study Group is a Medicine article available to read on EtoBox.

What is Safety of Divalproex Sodium in Migraine Prophylaxis: An Open-Label, Long-term Study about?

Long-term Safety of Depakote in Headache Prophylaxis Study Group Context.-The adverse event profile of long-term divalproex therapy for epilepsy is well established, but little is known about the tolerability or safety of divalproex in long-term migraine prophylaxis. Objective.-Evaluate the long-term safety and efficacy of divalproex sodium in migraine prophylaxis. Design.-Open-label, long-term study, of up to 3 years, of patients who completed one of two multicenter, double-blind, randomized, placebo-controlled studies. Setting.-Eighteen headache/neurology centers throughout the United States. Patients.-One hundred sixty-three patients: 46 treated with placebo, 117 treated with divalproex for migraine in previous studies. Intervention.-Divalproex therapy initiated at 500 mg/day (250 mg twice daily), with adjustment in dose and dosing frequency possible after 1 to 3 days. Main Outcome Measures.-Number and proportion of patients reporting treatment-emergent adverse events, prevalence and incidence for each treatment-emergent adverse event, vital signs, body weight, 4-week migraine rates and proportion of patients with 50% or greater reduction in rate over time. Results.-Treatment la

Who reads Safety of Divalproex Sodium in Migraine Prophylaxis: An Open-Label, Long-term Study?

Author

Stephen D. Silberstein; Stephen D. Collins; Long-term Safety of Depakote in Headache Prophylaxis Study Group

Publisher

John Wiley and Sons; Wiley (Blackwell Publishing); Blackwell Publishing Inc.; Wiley (ISSN 0017-8748)

Published

1999

Language

EN

Field

Medicine (Health Sciences)